To evaluate the safety and tolerability of ranibizumab in patients with CME secondary to non-ischemic retinopathy 2 years [clinicaltrials_resource:430d58d27e709a286872bf58ff8c60bb]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To evaluate the safety and tolerability of ranibizumab in patients with CME secondary to non-ischemic retinopathy 2 years [clinicaltrials_resource:430d58d27e709a286872bf58ff8c60bb]
Bio2RDF identifier
430d58d27e709a286872bf58ff8c60bb
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:430d58d27e709a286872bf58ff8c60bb
measure [clinicaltrials_vocabulary:measure]
To evaluate the safety and tol ...... ry to non-ischemic retinopathy
time frame [clinicaltrials_vocabulary:time-frame]
identifier
clinicaltrials_resource:430d58d27e709a286872bf58ff8c60bb
title
To evaluate the safety and tol ...... n-ischemic retinopathy 2 years
@en
type
label
To evaluate the safety and tol ...... d58d27e709a286872bf58ff8c60bb]
@en